1. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 27

    Next generation product aerosol bubbled extracts show little to no effect in high content screening endpoints when compared to cigarette smoke bubbled extracts

    TRELLES STICKEN E.(1); WIECZOREK R.(1); BODE L.M.(1); SIMMS L.(2); STEVENSON M.(2)
    (1) Reemtsma Cigarettenfabriken GmbH (an Imperial Brands PLC Company), BioToxLab, Hamburg, Germany; (2) Imperial Tobacco Limited, In vitro Research, Bristol, U.K.
    Tobacco-based and tobacco-free next generation products (NGPs) are understood to be a less harmful alternative to conventional combustible cigarettes. The objective of this study was to compare the in vitro biological response of cigarette smoke...
  2. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 37

    Use of cell media nicotine concentration as a marker to predict cells surface deposited nicotine in transwells after fresh smoke/aerosol exposure

    WIECZOREK R.(1); TRELLES STICKEN E.(1); BODE L.M.(1); SIMMS l.(2)
    (1) Reemtsma Cigarettenfabriken GmbH (an Imperial Brands PLC Company), Hamburg, Germany; (2) Imperial Tobacco Limited, Bristol, U.K.
    Exposure of organotypic 3D lung models at the air liquid interface (ALI) to fresh whole smoke/aerosol provides a more human relevant exposure assessment of combustible cigarettes and e-vapour products. The aim of this study is to present a method...
  3. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 56

    Perceptions of the relative harm of electronic cigarettes compared with smoking in the U.S.A.: analysis of the Population Assessment of Tobacco and Health (PATH) study data, 2013-2016

    O’CONNELL G.(1); WALELE T.(1); CAHOURS X.(2); THOMPSON J.(1); VERRON T.(2)
    (1) Imperial Tobacco Limited, Bristol, U.K.; (2) SEITA - Imperial Brands, Paris, France
    Electronic cigarettes (e-cigarettes) have been characterised as significantly less harmful than smoked tobacco by an increasing number of public health authorities. Despite this, U.S. adults remain poorly informed about the relative risk of these...
  4. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 58

    A consortium approach for consumer-reported outcome measures to assess tobacco- and nicotine-containing products

    ACQUADRO C.(1) on behalf of the CORESTA CROM Task Force: AYALA-FIERRO F.(2); BLACK R.(3); CAHOURS X.(4); CHREA C.(5); CURTIN G.(6); GILES L.(7); McCAFFREY S.(3); PARK C.H.(8); PRASAD K.(9); SHERWOOD N.(10); SHIFFMAN S.(11); SMITH J.(6); SPIES E.(5)
    (1) Mapi Research Trust, Lyon, France; (2) ITG Brands, Greensboro, NC, U.S.A.; (3) Altria Client Services, Richmond, VA, U.S.A.; (4) SEITA - Imperial Brands, Paris, France; (5) Philip Morris Products S.A., Neûchatel, Switzerland; (6) RAIS, Winston-Salem, NC, U.S.A.; (7) JT Int'l SA, Genève, Switzerland; (8) KT&G Research Institute, Daejeon, Republic of Korea; (9) British American Tobacco, Southampton, U.K.; (10) Neil Sherwood Consulting, Commugny, Switzerland; (11) Pinney Associates, Pittsburgh, PA, U.S.A.
    In the tobacco space, consumer-reported outcome measures (CROM) are essential for understanding motivations, subjective effects, and behavior. Such measures have become particularly important with the advent of candidate modified risk tobacco...
  5. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, ST 62

    Overview of in vitro methods used to assess e-cigarettes based on “Toxicity Testing in 21st Century” principles

    SIMMS L.(1); STEVENSON M.(1); CZEKALA L.(1); TSCHIERSKE N.(1); WALELE T.(2)
    (1) Imperial Tobacco Ltd, Bristol, U.K.; (2) Fontem Ventures B.V. (an Imperial Brands PLC Company), Amsterdam, The Netherlands
    When the National Academies of Sciences released “Toxicity Testing in the 21st Century: A Vision and a Strategy” a new toxicological paradigm was created, focusing on the use of human cell lines and the disruption of key cellular pathways. In keeping...
  6. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, STPOST 21

    The use of in vitro human biomarkers from relevant primary cell lines, to assess the effects of increasing nicotine concentration in e-liquids

    SIMMS L.(1); STEVENSON M.(1); CZEKALA L.(1); TSCHIERSKE N.(1); BERG E.(2); WALELE T.(3)
    (1) Imperial Tobacco Ltd, Bristol, U.K.; (2) DiscoverX Corporation, Fremont, CA, U.S.A.; (3) Fontem Ventures B.V. (an Imperial Brands PLC Company), Amsterdam, The Netherlands
    As part of the ongoing stewardship of electronic cigarettes, and in line with the National Academies of Sciences “Toxicity Testing in the 21st Century: A Vision and a Strategy”, Fontem Ventures B.V. have investigated the utility of a series of...
  7. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, STPOST 22

    Dosimetry: TPM and nicotine delivery of combusted tobacco products to the 24 and 96 Multi Well Plate and inserts on Smoke Aerosol Exposure In Vitro System (SAEIVS)

    WIECZOREK R.(1); TRELLES STICKEN E.(1); BODE L.M.(1); SIMMS L.(2)
    (1) Reemtsma Cigarettenfabriken GmbH (an Imperial Brands PLC Company), Hamburg, Germany; (2) Imperial Tobacco Limited, Bristol, U.K.
    In vitro exposure systems are key tools for the risk assessment of emerging electronic nicotine delivery systems as well as for conventional tobacco products. The Smoke Aerosol Exposure in vitro System (SAEIVS) used at Imperial Tobacco Limited is...
  8. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, STPOST 23

    Dosimetry: the effects of cigarette smoke dilution on nicotine delivery in a 24 and 96 well format using Smoke Aerosol Exposure In Vitro System (SAEIVS)

    BODE L.M.(1); ROEWER K.(1); OTTE S.(1); WIECZOREK R.(1); SIMMS L.(2)
    (1) Reemtsma Cigarettenfabriken GmbH (an Imperial Brands PLC Company), Hamburg, Germany; (2) Imperial Tobacco Limited, Bristol, U.K.
    In vitro aerosol exposure systems are useful tools for screening of potential toxic effects of freshly generated smoke of conventional cigarettes[1]. An in house platform “Smoke Aerosol Exposure In Vitro System (SAEIVS)” (assembled by Burghart...
  9. CORESTA Meeting, Smoke Science/Product Technology, 2015, Jeju, ST 07

    Which parameters are suitable to evaluate e-vapour products puffing behaviour?

    TROUDE V.(1); WALELE T.(2); VERRON T.(1); DUPUTIE G.(1); PERROT R.(1)
    (1) SEITA, Imperial Tobacco Group, Fleury-les-Aubrais, France; (2) Imperial Tobacco Group, Bristol, U.K.
    The growing popularity of e-vapour products (EVP) carries with it an increasing interest in the examination of vaping behaviour. As part of a product stewardship programme to evaluate and assess e-vapour products prior to placing them on the...